Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 9,540 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: HEARTS Clear all

Conditions: Coronary Artery Disease, Stable Angina, Unstable Angina, Non-ST-Elevation Myocardial Infarction
Interventions: MedHub AutocathFFR; Device
Lead sponsor: Medhub Ltd.; Industry
Eligibility: 23 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Gainesville, Georgia + 1 more

Conditions: Aortic Valve Stenosis
Interventions: SAPIEN 3 THV, Optimal Heart Failure Therapy; Device · Biological
Lead sponsor: Cardiovascular Research Foundation, New York; Other
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 46
States / cities: Chandler, Arizona • La Jolla, California • Los Angeles, California + 37 more

Conditions: Cardiac Catheterization, Blood Pressure, Heart Ventricles, Echocardiography, Heart Failure
Interventions: Definity; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 21 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
Interventions: AtriCure CryoICE & AtriClip LAA Exclusion; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 15
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 10 more

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions: Biopsy Procedure, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tazemetostat Hydrobromide, Trametinib Dimethyl Sulfoxide; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 17
States / cities: Aventura, Florida • Coral Gables, Florida • Deerfield Beach, Florida + 11 more

Conditions: COVID-19, Upper Respiratory Infection, Lower Respiratory Infection
Interventions: Fitbit, Douglas Bag, Periflux 6000 EPOS, BIOPAC, Flowmet, NIRS; Device
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 78 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congestive Heart Failure, Atrial Arrhythmia, Atrial Tachyarrhythmia, Atrial Fibrillation
Interventions: Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 30
States / cities: Anchorage, Alaska • Phoenix, Arizona • Santa Monica, California + 27 more

Conditions: Coronary Artery Bypass Grafting
Interventions: Vein Harvesting Procedures; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 16
States / cities: Tucson, Arizona • San Francisco, California • Gainesville, Florida + 13 more

Conditions: Coronary Artery Disease
Interventions: FFRangio; Device
Lead sponsor: CathWorks Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Stanford, California • New York, New York • Roslyn, New York + 1 more

Conditions: Heart Failure
Interventions: Telemonitoring, Flexible Diuretic Regimen; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744, GSK1265744 matching placebo, Moxifloxacin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Chronic Kidney Diseases
Interventions: Exercise, Stretching; Behavioral
Lead sponsor: University of North Texas, Denton, TX; Other
Eligibility: 30 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Denton, Texas

Conditions: Obesity, Cardiovascular Risk Factors
Interventions: Stepped Care; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 25 Years to 70 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Hypertrophic Cardiomyopathy (HCM)
Interventions: myocardial contrast echo; Diagnostic Test
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Aortic Stenosis
Interventions: 18F-NaF; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Parkinson Disease
Interventions: Moderate Exercise, Vigorous Exercise, No Intervention; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 80 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Aurora, Colorado • Chicago, Illinois • Pittsburgh, Pennsylvania

Conditions: Cognitive Impairment, Cardiovascular Risk Factor
Interventions: Mindfulness training, Aerobic training; Behavioral
Lead sponsor: The Miriam Hospital; Other
Eligibility: 55 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Acute Myocardial Infarction (AMI)
Interventions: Not listed
Lead sponsor: Rohan Dharmakumar; Other
Eligibility: 18 Years to 79 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Kidney Disease, End Stage Kidney Disease, Cardiovascular Disease
Interventions: exercise training; Behavioral
Lead sponsor: MaineHealth; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Diastolic Dysfunction, Systolic Dysfunction, Diastolic Heart Failure
Interventions: Sulforaphane; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 60 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Obesity, Insulin Resistance, Triglycerides, Diabetes
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Coronary Artery Disease, Valvular Heart Disease, Aorta Disease, Heart Failure
Interventions: Sugammadex administration; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: de Novo Heart Failure
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 9,870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency
Interventions: Contour 3D® implant for tricuspid valve repair, Tri-Ad® implant for tricuspid valve repair; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: Aventura, Florida • Ann Arbor, Michigan • Asheville, North Carolina

Search by objective public record fields.

Validation of the MedHub AutocathFFR Software Device for Non-Invasive Fractional Flow Reserve (FFR)

Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement

AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

A Noninvasive Multimodal Biosensing Device for Screening and Monitoring Response to Treatment of Infectious Respiratory Diseases

Clinical Investigation of the Medtronic Concerto™ Device

Randomized Endo-Vein Graft Prospective

FFRangio Accuracy vs. Standard FFR

University of Michigan Advanced Heart Failure Tele-Monitoring and Flexible Diuretic Project

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Cerebrovascular Dysregulation in Chronic Kidney Disease

Planned CORR: Planned Care for Obesity and Risk Reduction

Perfusion Abnormalities in Hypertrophic Cardiomyopathy

18-F Sodium Fluoride (18F-NaF) PET for the Assessment of Bioprosthetic Aortic Valve Durability and Outcomes

Study in Parkinson's Disease of Exercise

The Active Mind Study

Acute MI UDMI Staging Diagnosis by High-sensitivity Cardiac Troponin-I

Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program

Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

Identifying Risk for Diabetes and Heart Disease in Women

Sugammadex Titration in Cardiac Surgery Patients

Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients

Contour 3D®/TriAd® Tricuspid Annuloplasty Ring Post-Market Clinical Trial